Oxford Biomedica broadens 5T4 antibody deal with Pfizer
Diagnostic rights secured for Investigational New Drug application
Oxford BioMedica has expanded its collaboration with Pfizer to develop therapeutic products targeting the company's proprietary 5T4 tumour antigen for the treatment of cancer.
The amended agreement grants Pfizer non-exclusive rights to the diagnostic use of 5T4 antibodies against the antigen and includes an option to commercialise a 5T4-based diagnostic.
Oxford BioMedica, a UK-based gene therapy company, could earn up to US$4m in upfront, development and commercial milestone payments, in addition to revenues from further commercialisation.
The original licensing agreement was signed with Wyeth (acquired by Pfizer in 2009) in 2001, and granted global rights to market antibodies targeting the 5T4 tumour antigen for all human cancer indications. Prior to this amendment, the potential value of the agreement for Oxford BioMedica was US$24m.
Additionally, under the agreement, Oxford BioMedica will receive royalties on sales of products targeting the proprietary 5T4 antigen that are developed and commercialised by Pfizer. The next milestone payment to Oxford BioMedica would be due if Pfizer initiates clinical trials.
